Ellen Burnham
Concepts (558)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 39 | 2025 | 813 | 6.470 |
Why?
| | Respiratory Insufficiency | 11 | 2026 | 323 | 2.070 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 628 | 1.920 |
Why?
| | Intensive Care Units | 21 | 2025 | 912 | 1.820 |
Why?
| | Lung | 19 | 2025 | 4084 | 1.680 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 120 | 1.610 |
Why?
| | Cannabis | 5 | 2025 | 509 | 1.290 |
Why?
| | Pneumonia | 9 | 2023 | 627 | 1.260 |
Why?
| | Ethanol | 11 | 2022 | 625 | 1.230 |
Why?
| | Acute Lung Injury | 10 | 2022 | 300 | 1.230 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 321 | 1.200 |
Why?
| | Critical Illness | 21 | 2024 | 886 | 1.130 |
Why?
| | Marijuana Smoking | 3 | 2025 | 249 | 1.070 |
Why?
| | Hospitalization | 10 | 2025 | 2440 | 1.070 |
Why?
| | Sepsis | 6 | 2020 | 642 | 1.040 |
Why?
| | Gene Expression | 3 | 2020 | 1474 | 1.000 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 368 | 0.990 |
Why?
| | Patient Admission | 2 | 2025 | 219 | 0.980 |
Why?
| | Cytokines | 9 | 2025 | 2043 | 0.940 |
Why?
| | Middle Aged | 76 | 2026 | 35892 | 0.920 |
Why?
| | Critical Care | 10 | 2021 | 695 | 0.900 |
Why?
| | Survivors | 8 | 2025 | 518 | 0.880 |
Why?
| | Inflammation Mediators | 4 | 2016 | 503 | 0.860 |
Why?
| | Adult | 69 | 2025 | 40408 | 0.820 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 83 | 0.810 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 383 | 0.810 |
Why?
| | Acetates | 2 | 2021 | 80 | 0.800 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 62 | 0.800 |
Why?
| | Stem Cells | 5 | 2015 | 621 | 0.770 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 176 | 0.770 |
Why?
| | Humans | 134 | 2026 | 144298 | 0.770 |
Why?
| | Smoking | 8 | 2021 | 1466 | 0.760 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 392 | 0.750 |
Why?
| | Hospital Mortality | 7 | 2025 | 1028 | 0.740 |
Why?
| | Mentors | 4 | 2014 | 214 | 0.740 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 187 | 0.740 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 572 | 0.740 |
Why?
| | Lung Diseases | 3 | 2021 | 780 | 0.720 |
Why?
| | Male | 84 | 2026 | 72263 | 0.710 |
Why?
| | Female | 86 | 2026 | 78137 | 0.700 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 287 | 0.680 |
Why?
| | Behavior | 1 | 2021 | 90 | 0.650 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 216 | 0.640 |
Why?
| | Thalamus | 2 | 2021 | 126 | 0.640 |
Why?
| | Glycerophospholipids | 4 | 2024 | 39 | 0.640 |
Why?
| | Case-Control Studies | 14 | 2022 | 3595 | 0.630 |
Why?
| | Respiration, Artificial | 13 | 2025 | 709 | 0.620 |
Why?
| | Burnout, Professional | 4 | 2022 | 483 | 0.610 |
Why?
| | Burns | 5 | 2025 | 369 | 0.600 |
Why?
| | Hallucinogens | 1 | 2021 | 109 | 0.590 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1085 | 0.590 |
Why?
| | Cigarette Smoking | 2 | 2020 | 99 | 0.580 |
Why?
| | Glutathione | 5 | 2016 | 364 | 0.560 |
Why?
| | RNA, Messenger | 5 | 2020 | 2808 | 0.560 |
Why?
| | Antioxidants | 4 | 2016 | 542 | 0.560 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 47 | 0.540 |
Why?
| | Epithelial Cells | 4 | 2021 | 1102 | 0.540 |
Why?
| | Tobacco Products | 1 | 2019 | 84 | 0.540 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 126 | 0.530 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 322 | 0.530 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 24 | 0.530 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 601 | 0.530 |
Why?
| | Physicians, Women | 1 | 2019 | 88 | 0.520 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 88 | 0.520 |
Why?
| | Inflammation | 8 | 2025 | 2862 | 0.510 |
Why?
| | Biomedical Research | 2 | 2021 | 712 | 0.490 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 276 | 0.490 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 11 | 0.480 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 53 | 0.470 |
Why?
| | Aged | 36 | 2026 | 25901 | 0.470 |
Why?
| | Marijuana Abuse | 1 | 2018 | 210 | 0.470 |
Why?
| | Alcohol Drinking | 6 | 2025 | 823 | 0.460 |
Why?
| | Biomarkers | 16 | 2026 | 4248 | 0.450 |
Why?
| | Retrospective Studies | 25 | 2025 | 17104 | 0.450 |
Why?
| | Azithromycin | 1 | 2015 | 105 | 0.440 |
Why?
| | Tomography | 2 | 2025 | 45 | 0.430 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 919 | 0.420 |
Why?
| | Electric Impedance | 2 | 2025 | 110 | 0.420 |
Why?
| | Research Support as Topic | 2 | 2011 | 79 | 0.410 |
Why?
| | Hypoxia | 4 | 2026 | 1193 | 0.400 |
Why?
| | Professional Autonomy | 1 | 2013 | 29 | 0.400 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 172 | 0.400 |
Why?
| | Cells, Cultured | 8 | 2018 | 4102 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2741 | 0.390 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 854 | 0.390 |
Why?
| | Bronchoscopy | 3 | 2023 | 226 | 0.380 |
Why?
| | Oxidative Stress | 5 | 2017 | 1331 | 0.380 |
Why?
| | Immunity, Innate | 1 | 2018 | 842 | 0.370 |
Why?
| | Asthma | 2 | 2022 | 1770 | 0.370 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 24 | 0.350 |
Why?
| | Academic Medical Centers | 2 | 2014 | 545 | 0.340 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 287 | 0.340 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 579 | 0.330 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 325 | 0.330 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2589 | 0.320 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.310 |
Why?
| | Malondialdehyde | 2 | 2021 | 30 | 0.310 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.310 |
Why?
| | Muscular Diseases | 3 | 2017 | 108 | 0.300 |
Why?
| | United States | 18 | 2026 | 15979 | 0.300 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 98 | 0.300 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 80 | 0.300 |
Why?
| | Personnel Selection | 1 | 2011 | 93 | 0.300 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 103 | 0.300 |
Why?
| | Cohort Studies | 13 | 2020 | 5948 | 0.290 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1920 | 0.290 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 119 | 0.290 |
Why?
| | Smokers | 2 | 2021 | 137 | 0.280 |
Why?
| | Prevalence | 4 | 2025 | 2836 | 0.280 |
Why?
| | Epidemics | 2 | 2019 | 98 | 0.270 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.270 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 241 | 0.270 |
Why?
| | Airway Extubation | 3 | 2013 | 60 | 0.260 |
Why?
| | Sexism | 2 | 2019 | 69 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 284 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1206 | 0.250 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.250 |
Why?
| | Benzodiazepines | 2 | 2025 | 168 | 0.250 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 193 | 0.250 |
Why?
| | Pilot Projects | 6 | 2025 | 1880 | 0.250 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1537 | 0.250 |
Why?
| | Naltrexone | 2 | 2025 | 118 | 0.250 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 240 | 0.250 |
Why?
| | Deglutition Disorders | 3 | 2013 | 148 | 0.240 |
Why?
| | Fibronectins | 1 | 2007 | 132 | 0.240 |
Why?
| | Endothelial Cells | 4 | 2011 | 862 | 0.240 |
Why?
| | APACHE | 4 | 2013 | 66 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1359 | 0.240 |
Why?
| | Marijuana Use | 2 | 2022 | 212 | 0.240 |
Why?
| | Young Adult | 13 | 2024 | 14092 | 0.240 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 168 | 0.230 |
Why?
| | Administration, Inhalation | 3 | 2025 | 569 | 0.230 |
Why?
| | Immunity, Cellular | 2 | 2018 | 272 | 0.230 |
Why?
| | Preoperative Care | 1 | 2008 | 378 | 0.230 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 8 | 0.230 |
Why?
| | Risk Factors | 16 | 2020 | 10783 | 0.230 |
Why?
| | Anesthesiology | 1 | 2008 | 176 | 0.230 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1178 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.220 |
Why?
| | Pediatrics | 1 | 2013 | 1118 | 0.220 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 55 | 0.220 |
Why?
| | Arachidonic Acids | 1 | 2025 | 43 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 385 | 0.220 |
Why?
| | Flow Cytometry | 2 | 2024 | 1152 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 379 | 0.220 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 51 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 85 | 0.210 |
Why?
| | Endocannabinoids | 1 | 2025 | 57 | 0.210 |
Why?
| | tau Proteins | 1 | 2025 | 115 | 0.210 |
Why?
| | Dysbiosis | 2 | 2024 | 187 | 0.210 |
Why?
| | Immunity | 1 | 2025 | 139 | 0.210 |
Why?
| | E-Selectin | 1 | 2004 | 61 | 0.200 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 880 | 0.200 |
Why?
| | Bacterial Proteins | 1 | 2010 | 958 | 0.200 |
Why?
| | Patient Discharge | 3 | 2024 | 985 | 0.200 |
Why?
| | Quality of Life | 2 | 2013 | 3180 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 318 | 0.200 |
Why?
| | Anticoagulants | 2 | 2019 | 726 | 0.200 |
Why?
| | Interleukin-1beta | 2 | 2017 | 390 | 0.190 |
Why?
| | Shock, Septic | 2 | 2022 | 216 | 0.190 |
Why?
| | Central Nervous System | 1 | 2025 | 278 | 0.190 |
Why?
| | Drug Prescriptions | 1 | 2025 | 283 | 0.190 |
Why?
| | Aged, 80 and over | 10 | 2022 | 8265 | 0.190 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 204 | 0.190 |
Why?
| | Internship and Residency | 1 | 2013 | 1261 | 0.190 |
Why?
| | Interferons | 2 | 2016 | 184 | 0.190 |
Why?
| | Dyspnea | 2 | 2019 | 250 | 0.190 |
Why?
| | Polyneuropathies | 2 | 2017 | 57 | 0.190 |
Why?
| | Lung Injury | 2 | 2016 | 236 | 0.190 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 22 | 0.180 |
Why?
| | Epithelium | 2 | 2021 | 309 | 0.180 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 29 | 0.180 |
Why?
| | Age Factors | 4 | 2021 | 3324 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 436 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 104 | 0.170 |
Why?
| | Interleukin-8 | 3 | 2018 | 269 | 0.170 |
Why?
| | Fibroblasts | 3 | 2013 | 1017 | 0.170 |
Why?
| | Double-Blind Method | 4 | 2014 | 2032 | 0.170 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.170 |
Why?
| | Societies, Medical | 2 | 2025 | 890 | 0.170 |
Why?
| | Cell Count | 2 | 2015 | 320 | 0.170 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.170 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.170 |
Why?
| | Interleukin-6 | 3 | 2026 | 770 | 0.170 |
Why?
| | Neutrophils | 3 | 2017 | 1115 | 0.160 |
Why?
| | Feces | 1 | 2024 | 513 | 0.160 |
Why?
| | Phagocytosis | 2 | 2014 | 294 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 654 | 0.160 |
Why?
| | Physicians | 3 | 2022 | 948 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 364 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1693 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 339 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1652 | 0.160 |
Why?
| | Animals | 18 | 2025 | 37800 | 0.150 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.150 |
Why?
| | Permeability | 2 | 2012 | 168 | 0.150 |
Why?
| | Capacity Building | 1 | 2020 | 62 | 0.150 |
Why?
| | Career Choice | 2 | 2012 | 233 | 0.150 |
Why?
| | Chemokines | 2 | 2018 | 217 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1142 | 0.150 |
Why?
| | von Willebrand Factor | 1 | 2019 | 85 | 0.150 |
Why?
| | Homeostasis | 1 | 2003 | 635 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Disaster Planning | 1 | 2020 | 101 | 0.150 |
Why?
| | Cardiology | 1 | 2022 | 359 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2022 | 301 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 36 | 0.140 |
Why?
| | Macrolides | 1 | 2019 | 69 | 0.140 |
Why?
| | Needs Assessment | 1 | 2021 | 401 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 948 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2395 | 0.140 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 427 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Brain | 3 | 2021 | 2929 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2006 | 944 | 0.140 |
Why?
| | Pyridines | 2 | 2010 | 601 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 24 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 175 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 26 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 82 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 27 | 0.140 |
Why?
| | Length of Stay | 4 | 2020 | 1338 | 0.130 |
Why?
| | Cardiologists | 1 | 2018 | 47 | 0.130 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 383 | 0.130 |
Why?
| | Decision Making | 1 | 2025 | 972 | 0.130 |
Why?
| | Hospitals, University | 2 | 2015 | 176 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 242 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 112 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 109 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 961 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 187 | 0.130 |
Why?
| | Pyrazoles | 1 | 2001 | 510 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 971 | 0.120 |
Why?
| | Tobacco Use | 1 | 2017 | 62 | 0.120 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 475 | 0.120 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 165 | 0.120 |
Why?
| | Cystine | 1 | 2016 | 17 | 0.120 |
Why?
| | Interleukin-10 | 1 | 2018 | 308 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 549 | 0.120 |
Why?
| | Feasibility Studies | 3 | 2026 | 1098 | 0.120 |
Why?
| | Disulfides | 1 | 2016 | 94 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4525 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 834 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2022 | 11713 | 0.120 |
Why?
| | Teichoic Acids | 1 | 2016 | 18 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 342 | 0.120 |
Why?
| | Hospitalists | 1 | 2020 | 267 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 288 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 771 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5404 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 175 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 334 | 0.110 |
Why?
| | RNA Splicing | 1 | 2017 | 286 | 0.110 |
Why?
| | Inflammasomes | 1 | 2017 | 145 | 0.110 |
Why?
| | Proteins | 2 | 2021 | 1011 | 0.110 |
Why?
| | Hospitals | 1 | 2020 | 727 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.110 |
Why?
| | Cysteine | 1 | 2016 | 207 | 0.110 |
Why?
| | Patient Selection | 2 | 2023 | 721 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2017 | 192 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2017 | 245 | 0.110 |
Why?
| | Acetylcysteine | 1 | 2016 | 136 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 182 | 0.110 |
Why?
| | Cholesterol | 1 | 2017 | 402 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 691 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 275 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5182 | 0.110 |
Why?
| | Prospective Studies | 7 | 2026 | 7972 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1073 | 0.110 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 161 | 0.100 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2917 | 0.100 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 62 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1263 | 0.100 |
Why?
| | Third-Party Consent | 1 | 2013 | 21 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1034 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 93 | 0.100 |
Why?
| | Competency-Based Education | 1 | 2014 | 81 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2321 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 40 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 412 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 29 | 0.100 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 41 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3408 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2017 | 408 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 78 | 0.090 |
Why?
| | Financial Support | 1 | 2012 | 17 | 0.090 |
Why?
| | Disease Progression | 1 | 2020 | 2844 | 0.090 |
Why?
| | Interleukin-12 | 1 | 2013 | 117 | 0.090 |
Why?
| | Logistic Models | 5 | 2017 | 2112 | 0.090 |
Why?
| | Aging | 2 | 2017 | 1935 | 0.090 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 23 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1287 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1092 | 0.090 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1465 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 63 | 0.090 |
Why?
| | Informed Consent | 1 | 2013 | 196 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 290 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 49 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 1029 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 293 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 83 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 86 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 74 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 160 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3879 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 541 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 832 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 689 | 0.080 |
Why?
| | Capillaries | 2 | 2009 | 118 | 0.080 |
Why?
| | Genetic Testing | 1 | 2013 | 479 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1128 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 78 | 0.080 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.080 |
Why?
| | After-Hours Care | 1 | 2010 | 16 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 450 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 283 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 71 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1504 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 615 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 95 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 2033 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 160 | 0.080 |
Why?
| | Colorado | 5 | 2024 | 4554 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 781 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1565 | 0.070 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 236 | 0.070 |
Why?
| | Program Development | 1 | 2011 | 368 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Mice | 7 | 2022 | 18218 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 425 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Peer Group | 1 | 2011 | 256 | 0.070 |
Why?
| | Computers | 1 | 2008 | 67 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1946 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5954 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 115 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 566 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 152 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 99 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 41 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 329 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 341 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2012 | 0.070 |
Why?
| | Schools | 1 | 2011 | 449 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 146 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 206 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 26 | 0.060 |
Why?
| | Cell Separation | 3 | 2016 | 302 | 0.060 |
Why?
| | Respiration Disorders | 1 | 2007 | 78 | 0.060 |
Why?
| | Indicators and Reagents | 1 | 2007 | 106 | 0.060 |
Why?
| | Georgia | 2 | 2004 | 79 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 452 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 132 | 0.060 |
Why?
| | Sex Factors | 1 | 2013 | 2103 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 408 | 0.060 |
Why?
| | Thrombocytopenia | 2 | 2019 | 202 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 146 | 0.060 |
Why?
| | Body Fluids | 1 | 2007 | 70 | 0.060 |
Why?
| | Patient Readmission | 3 | 2019 | 762 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1124 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 941 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 190 | 0.060 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 143 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 659 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5862 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 113 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 371 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 125 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 79 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1981 | 0.050 |
Why?
| | Louisiana | 1 | 2024 | 28 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 204 | 0.050 |
Why?
| | Observation | 1 | 2004 | 54 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22370 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 60 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 807 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 144 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2860 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1489 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 7128 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6035 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 350 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 24 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 76 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 56 | 0.040 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 76 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 82 | 0.040 |
Why?
| | North America | 1 | 2022 | 312 | 0.040 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.040 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 144 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 195 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 6 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 357 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 197 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 171 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3106 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 252 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 661 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 888 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 23 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1360 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5553 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 64 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 436 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2886 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1809 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4293 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 22 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 331 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 170 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 355 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2018 | 133 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 50 | 0.030 |
Why?
| | Illinois | 1 | 2017 | 47 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 399 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 46 | 0.030 |
Why?
| | Phenotype | 1 | 2026 | 3139 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1660 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 167 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 143 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 85 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 713 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 847 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 768 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 193 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1839 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 334 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1405 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 386 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2940 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 126 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 154 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 31 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2939 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 444 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 324 | 0.030 |
Why?
| | Risk | 1 | 2018 | 910 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 194 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 132 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 261 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 463 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 845 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 942 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 535 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 559 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 245 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 206 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 822 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1262 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2113 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 207 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 26 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1076 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2014 | 331 | 0.020 |
Why?
| | Ventilator Weaning | 1 | 2013 | 39 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1368 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 1020 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.020 |
Why?
| | Thymus Gland | 1 | 2014 | 311 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 416 | 0.020 |
Why?
| | Tidal Volume | 1 | 2013 | 111 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 547 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 143 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 147 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 741 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 353 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 522 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 61 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2241 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2512 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 512 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 732 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 104 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 89 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 422 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 199 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 184 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 552 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1182 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 98 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 264 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 847 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1763 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 572 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 56 | 0.020 |
Why?
| | Amides | 1 | 2010 | 98 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 462 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 600 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 382 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1702 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 722 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 42 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1762 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 237 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1078 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 165 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 18 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 30 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 48 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 54 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 87 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 65 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 981 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 80 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 42 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 779 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 24 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 77 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 263 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 71 | 0.020 |
Why?
| | Child | 2 | 2022 | 22562 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 253 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 1063 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 475 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 516 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 957 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 353 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 235 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1807 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 559 | 0.010 |
Why?
| | Adipocytes | 1 | 2008 | 223 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 332 | 0.010 |
Why?
| | Trauma Centers | 1 | 2009 | 465 | 0.010 |
Why?
| | Cell Lineage | 1 | 2008 | 376 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1739 | 0.010 |
Why?
| | Chondrocytes | 1 | 2008 | 232 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 552 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 249 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1501 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 425 | 0.010 |
Why?
| | France | 1 | 2003 | 40 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 89 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 985 | 0.010 |
Why?
| | Washington | 1 | 2003 | 147 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 178 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2485 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1300 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|